JP2025183279A5 - - Google Patents

Info

Publication number
JP2025183279A5
JP2025183279A5 JP2025146817A JP2025146817A JP2025183279A5 JP 2025183279 A5 JP2025183279 A5 JP 2025183279A5 JP 2025146817 A JP2025146817 A JP 2025146817A JP 2025146817 A JP2025146817 A JP 2025146817A JP 2025183279 A5 JP2025183279 A5 JP 2025183279A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide sequence
bcma
polynucleotide
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025146817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025183279A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/088836 external-priority patent/WO2020224606A1/zh
Application filed filed Critical
Publication of JP2025183279A publication Critical patent/JP2025183279A/ja
Publication of JP2025183279A5 publication Critical patent/JP2025183279A5/ja
Pending legal-status Critical Current

Links

JP2025146817A 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用 Pending JP2025183279A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910376652 2019-05-07
CN201910376652.8 2019-05-07
PCT/CN2020/088836 WO2020224606A1 (zh) 2019-05-07 2020-05-06 靶向bcma的工程化免疫细胞及其用途
JP2021566227A JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021566227A Division JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Publications (2)

Publication Number Publication Date
JP2025183279A JP2025183279A (ja) 2025-12-16
JP2025183279A5 true JP2025183279A5 (https=) 2026-02-17

Family

ID=73051240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566227A Active JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用
JP2025146817A Pending JP2025183279A (ja) 2019-05-07 2025-09-04 Bcmaを標的とする操作された免疫細胞及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021566227A Active JP7741732B2 (ja) 2019-05-07 2020-05-06 Bcmaを標的とする操作された免疫細胞及びその使用

Country Status (11)

Country Link
US (2) US11840575B2 (https=)
EP (1) EP3967329B1 (https=)
JP (2) JP7741732B2 (https=)
KR (1) KR20220017914A (https=)
CN (2) CN118184800A (https=)
AU (1) AU2020270298A1 (https=)
CA (1) CA3139346A1 (https=)
IL (1) IL287873A (https=)
SG (1) SG11202112382WA (https=)
TW (1) TWI771677B (https=)
WO (1) WO2020224606A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086055B2 (en) * 2016-06-01 2018-10-02 Promab Biotechnologies, Inc. Adherent cancer cell line expressing a hematological tumor antigen
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
TWI797610B (zh) * 2020-05-06 2023-04-01 大陸商亘喜生物科技(上海)有限公司 人源化cd19抗體及其應用
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CN112778427B (zh) * 2021-01-29 2022-03-15 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
CN114317607B (zh) * 2021-12-31 2024-08-02 苏州桑尼赛尔生物医药有限公司 融合一代靶向cd7 car和二代靶向bcma的双靶点通用car-t细胞及制备方法
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
CN117143248A (zh) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
EP4532695A1 (en) * 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体(car)及其制备方法
CN116063556B (zh) * 2022-08-18 2023-06-16 再少年(北京)生物科技有限公司 Ips来源的car-nk细胞及其治疗癌症的用途
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
CN116814553A (zh) * 2023-03-30 2023-09-29 广州百吉生物制药有限公司 杀伤和存续能力增强型car-t细胞及其制备和应用
CN116444669B (zh) * 2023-04-04 2024-02-13 科弈(浙江)药业科技有限公司 靶向bcma car-t细胞人源化抗体
WO2024215708A2 (en) * 2023-04-11 2024-10-17 AbelZeta Inc. Bispecific chimeric antigen receptors targeting bcma and cd19
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
CN117126891A (zh) * 2023-08-30 2023-11-28 广东君厚生物医药有限公司 一种逆转录病毒表达载体及包括其的car-t细胞
CN121320261A (zh) * 2024-07-12 2026-01-13 南京驯鹿生物技术股份有限公司 靶向bcma和gprc5d的双特异性car-t细胞
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP4303232A3 (en) * 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
MX383150B (es) 2014-06-02 2025-03-13 Us Health Receptores quiméricos de antígeno que tienen como diana a cd-19.
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-bcma嵌合抗原受體治療癌症
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
RU2018119706A (ru) 2015-10-30 2019-12-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ прогноза
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发(慕尼黑)股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
US20170233484A1 (en) * 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US20190336504A1 (en) * 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
SG11201903830TA (en) 2016-11-22 2019-05-30 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
AU2017370644A1 (en) 2016-12-05 2019-06-13 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
US20190381171A1 (en) * 2017-02-17 2019-12-19 Unum Therapeutics Inc. Co-use of anti-bcma antibody and antibody-coupled t cell receptor (actr) in cancer therapy and b cell disorders
AU2018269194B2 (en) * 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技(上海)有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
SG11202011383VA (en) 2018-05-31 2020-12-30 Univ Washington Chimeric antigen receptor t cells (car-t) for the treatment of cancer
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
CA3109959A1 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109485734B (zh) * 2018-12-30 2020-05-12 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3139346A1 (en) 2019-05-07 2020-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CN113784733B (zh) * 2019-05-07 2024-09-06 亘喜生物科技(上海)有限公司 靶向bcma的工程化免疫细胞及其用途
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CN115777017A (zh) * 2020-05-06 2023-03-10 亘喜生物科技(上海)有限公司 用于t细胞工程改造的组合物及方法
AU2024320048A1 (en) * 2023-08-10 2026-03-26 Gracell Biotechnologies (Shanghai) Co., Ltd. Use of dual-target car-t cells in treating b-cell autoimmune diseases

Similar Documents

Publication Publication Date Title
JP2025183279A5 (https=)
JPWO2020224606A5 (https=)
JP6669722B2 (ja) Cd3結合ドメイン
JP2022061992A5 (https=)
JP2012501670A5 (https=)
JP2021524267A5 (https=)
JP2019532625A5 (https=)
JP2021510521A5 (https=)
JP2024023228A5 (https=)
JP2012525829A5 (https=)
JP2021521793A5 (https=)
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
JP2010532764A5 (https=)
JP2011509245A5 (https=)
JPWO2019129221A5 (https=)
JP2022501065A5 (https=)
JPWO2021184673A5 (https=)
JPWO2020076992A5 (https=)
CA3240254A1 (en) Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
JP2022534433A (ja) 抗gal9免疫阻害性結合分子
JP2016529213A5 (https=)
JPWO2019204462A5 (https=)
JP2021529539A5 (https=)
CN115151572B (zh) 针对ror1的抗体及其用途
WO2024109585A1 (zh) 抗cd39抗体及其应用